INSMED INC Business Combination, Contingent Consideration, Liability, Current
INSMED INC (INSM) had Business Combination, Contingent Consideration, Liability, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2026-03-31: Business Combination, Contingent Consideration, Liability, Current $0.00.
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Current $57.80M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Current $42.50M.
| Period end | Business Combination, Contingent Consideration, Liability, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $57.80M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $42.50M 10-Q · filed 2025-10-30 |
| 2024-12-31 | $24.70M 10-K · filed 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |